Patent assignee · US · COMPANY

ARDELYX, INC.

🏢 View company profile →
39Patents
39Active
39Granted
54Portfolio score

Filing activity: Jun 29, 2011 → Dec 27, 2023

Most-cited patents

PatentTitleAreaCited byStatus
US8809339B2 Compounds and methods for inhibiting phosphate transport Chemistry; Metallurgy 7 Active
US8815908B2 Compounds and methods for inhibiting phosphate transport Chemistry; Metallurgy 7 Active
US8815910B2 Compounds and methods for inhibiting phosphate transport Chemistry; Metallurgy 7 Active
US9408840B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Emerging Cross-Sectional Technologies 6 Active
US10272079B2 NHE3-binding compounds and methods for inhibiting phosphate transport Human Necessities 5 Active
US8916569B2 Compounds and methods for inhibiting phosphate transport Chemistry; Metallurgy 5 Active
US8541448B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Emerging Cross-Sectional Technologies 4 Active
US10793568B2 Hormone receptor modulators for treating metabolic conditions and disorders Chemistry; Metallurgy 3 Active
US10543207B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Emerging Cross-Sectional Technologies 3 Active
US11091482B2 Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators Human Necessities 3 Active
US10376481B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Human Necessities 3 Active
US9433640B2 Compositions and methods for treating hyperkalemia Chemistry; Metallurgy 2 Active
US8969377B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Emerging Cross-Sectional Technologies 2 Active
US10392413B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists Chemistry; Metallurgy 2 Active
US10385024B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Emerging Cross-Sectional Technologies 2 Active
US10968246B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists Chemistry; Metallurgy 1 Active
US10940146B2 NHE3-binding compounds and methods for inhibiting phosphate transport Human Necessities 1 Active
US11318129B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Emerging Cross-Sectional Technologies 1 Active
US9006281B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Emerging Cross-Sectional Technologies 1 Active
US11242337B2 Compounds useful for treating gastrointestinal tract disorders Chemistry; Metallurgy 1 Active
US9867848B2 Compositions and methods for treating hyperkalemia Chemistry; Metallurgy 0 Active
US11768319B2 Glycyrrhetinic acid derivatives for treating hyperkalemia Physics 0 Active
US11718619B2 Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators Human Necessities 0 Active
US12281103B2 Compounds useful for treating gastrointestinal tract disorders Chemistry; Metallurgy 0 Active
US9919006B2 Compositions and methods for treating hyperkalemia Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.